Clinical Trial

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective, pilot, single-arm, single-center study exploring the efficacy and safety of savolitinib plus docetaxel as second-line therapy in patients with MET overexpressed, EGFR/ALK/ROS1/MET ex14m-wildtype advanced NSCLC. Participants will receive treatment of docetaxel (60 mg/m2, ivgtt, q3w) in combination with savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after informed consent signed. Treatment will continue until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn, other discontinuation criterion is met, or study completion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-17.
Status change: Not Yet Recruiting → Recruiting 2023-10-09
Trial Details
NCT Number NCT05777278
Lead Sponsor The First Affiliated Hospital of Guangzhou Medical University
Conditions Non-small Cell Lung Cancer
Enrollment 29 participants
Start Date 2023-07-26
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-10